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We have previously shown in a randomized open trial of
Prempak C 0.6254 versus no treatment that adductor
pollicis (AP) muscle strength increased in the treated
group over 39–52 weeks [1]. Those who were weakest at
the start of the trial benefited most, and the benefit
occurred in the absence of any commensurate change in
muscle size [1]. We have now tested whether this
increased strength relative to the control group is
maintained by re-measuring a representative sample of
the subjects 2–4 years after they had originally taken part
in the trial.
Of the 87 subjects who completed the original trial, 72
agreed to take part. These subjects gave written informed
consent for the follow-up study, which had been
approved by the UCL}UCLH ethical committee. Five
of these 72 were excluded on the basis of the original
criteria, which they had developed since the end of the
trial, 12 more of the original control group were excluded
because they had taken hormone replacement therapy
(HRT) for variable periods of time since the completion
of the trial. Of the remaining 55 subjects, 25 women had
previously been randomized to be controls and 30 to
take HRT. Of these 30, 11 subjects had continued HRT
treatment until follow-up. The 55 subjects used in the
follow-up study were representative of the whole group
who had completed the original trial in terms of age
(60.4‡0.4 years versus 60.8‡0.3 years ; means‡S.E.M.)
and original AP muscle strength (59.5‡1.2 N versus
58.5‡0.8 N). The new observations were made over a
period of 5 months, and consisted of measuring maximum
voluntary force (MVF) and cross-sectional area (CSA) of
AP as previously described [2,3], but using, for the force
measurements, new equipment with minor mechanical
design changes. The follow-up observations were also
made by a different observer. The results show a larger
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Figure 1 Benefit of HRT on AP muscle strength at 1 year and
at 3.5 years
Data are differences between the mean MVF of treated versus control groups. The
error bars show means‡S. E. M. (E) Results from the original study [1], offset
slightly to the right for clarity ; (D) subjects who continued HRT throughout the
4.5 year period ; and (^) subjects who had discontinued HRT on average 1.7
years before the final measurement.
than expected fall in absolute MVF for both control and
treated groups since the end of the study. We cannot be
certain of the extent to which the change in equipment
and observer may have contributed to this apparent
decline in absolute force. For this reason, we have
analysed the data in terms of the differences between the
control and HRT groups, which cannot be influenced by
these uncertainties.
CSA showed no significant change in any of the groups
during the follow-up period, and there were no signifi-
cant differences between the groups. Figure 1 shows the
differences in MVF between those HRT users who had
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continued treatment and the controls, both at the start
and end of the original trial and 3.5 years later (open
circles). Most of the difference in muscle strength seen at
the end of the trial persisted during the subsequent 3.5
years. This benefit at 3.5 years amounted to 73% of that
at the end of the original trial (5% confidence limits,
28–117%). The Figure also confirms that this group is
representative by comparing their benefit at the end of
the trial (14.8‡3.1 N, means‡S.E.M.) with that in the
larger group (filled circles ; 39 HRT and 48 controls) who
completed the original study (13.39‡1.83 N). There is no
significant difference at the start or end of the trial
between the original groups and the samples used for the
follow-up (P " 0.6).
The open triangles (Figure 1) show results for the 19
subjects who had previously been in the intervention
group, but who had since stopped taking HRT, on
average 1.7 years prior to this follow-up. In this group,
the mean benefit remaining is 55% of that at the end of
the trial (confidence limits 7–103%). There is no sig-
nificant difference between the force at follow-up of
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those who continued HRT compared with those who had
stopped treatment (P fl 0.405, unpaired t test).
This follow-up has shown that the benefit of HRT on
AP muscle strength compared with a control group was
maintained in those who continued treatment beyond
1 year, although no further increase in muscle strength
was found. At least some benefit of HRT on muscle
strength remains for several years in those who dis-
continue it after 1 year or more of treatment.
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